-
1
-
-
84864413311
-
Recent advances in novel targeted therapies for HER2-positive breast cancer
-
22824822 10.1097/CAD.0b013e328352d292 1:CAS:528:DC%2BC38XhtVGnur3E
-
Murphy CG, Morris PG. Recent advances in novel targeted therapies for HER2-positive breast cancer. Anticancer Drugs. 2012;23:765-76.
-
(2012)
Anticancer Drugs
, vol.23
, pp. 765-776
-
-
Murphy, C.G.1
Morris, P.G.2
-
2
-
-
33845886440
-
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
-
17192538 10.1056/NEJMoa064320 1:CAS:528:DC%2BD2sXhslSqsA%3D%3D
-
Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355:2733-43.
-
(2006)
N Engl J Med
, vol.355
, pp. 2733-2743
-
-
Geyer, C.E.1
Forster, J.2
Lindquist, D.3
Chan, S.4
Romieu, C.G.5
Pienkowski, T.6
-
4
-
-
80053362290
-
Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer
-
10.1016/j.ejca.2011.06.021
-
von Minckwitz G, Schwedler K, Schmidt M, Barinoff J, Mundhenke C, Cufer T, et al. Loibl S; GBG 26/BIG 03-05 study group and participating investigators. Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. Eur J Cancer. 2011;47:2273-81.
-
(2011)
Eur J Cancer
, vol.47
, pp. 2273-2281
-
-
Von Minckwitz, G.1
Schwedler, K.2
Schmidt, M.3
Barinoff, J.4
Mundhenke, C.5
Cufer, T.6
-
5
-
-
84861516765
-
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: Mechanisms and clinical implications
-
22471661 10.1615/CritRevOncog.v17.i1.20
-
Rexer BN, Arteaga CL. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog. 2012;17:1-16.
-
(2012)
Crit Rev Oncog
, vol.17
, pp. 1-16
-
-
Rexer, B.N.1
Arteaga, C.L.2
-
6
-
-
79959226810
-
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: Evidence from a retrospective study
-
21479926 10.1007/s10549-011-1484-4 1:CAS:528:DC%2BC3MXnsVWlsr0%3D
-
Campiglio M, Bufalino R, Sandri M, Ferri E, Aiello RA, De Matteis A, et al. Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat. 2011;128:147-54.
-
(2011)
Breast Cancer Res Treat
, vol.128
, pp. 147-154
-
-
Campiglio, M.1
Bufalino, R.2
Sandri, M.3
Ferri, E.4
Aiello, R.A.5
De Matteis, A.6
-
7
-
-
0033402622
-
Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer
-
10643536 10.1023/A:1008318523058 1:STN:280:DC%2BD3c7gvVWnug%3D%3D
-
Spielmann M, Llombart A, Zelek L, Sverdlin R, Rixe O, Le Cesne A. Docetaxel-cisplatin combination (DC) chemotherapy in patients with anthracycline-resistant advanced breast cancer. Ann Oncol. 1999;10:1457-60.
-
(1999)
Ann Oncol
, vol.10
, pp. 1457-1460
-
-
Spielmann, M.1
Llombart, A.2
Zelek, L.3
Sverdlin, R.4
Rixe, O.5
Le Cesne, A.6
-
8
-
-
0038200673
-
Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer
-
12852694 10.1080/02841860310010709 1:CAS:528:DC%2BD3sXosFCntrg%3D
-
Airoldi M, Cattel L, Pedani F, Marchionatti S, Tagini V, Bumma C, et al. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/relapsed metastatic breast cancer. Acta Oncol. 2003;42:186-94.
-
(2003)
Acta Oncol
, vol.42
, pp. 186-194
-
-
Airoldi, M.1
Cattel, L.2
Pedani, F.3
Marchionatti, S.4
Tagini, V.5
Bumma, C.6
-
9
-
-
36849071808
-
Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment
-
17968020 10.1200/JCO.2007.12.6557 1:CAS:528:DC%2BD2sXhsVKnsbzO
-
Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210-7.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5210-5217
-
-
Thomas, E.S.1
Gomez, H.L.2
Li, R.K.3
Chung, H.C.4
Fein, L.E.5
Chan, V.F.6
-
10
-
-
77955448465
-
Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes
-
20454927 10.1007/s10549-010-0901-4 1:CAS:528:DC%2BC3cXnsFymu7g%3D
-
Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF, et al. Hurtado de Mendoza F, Xu B, Vahdat LT, Peck RA, Mukhopadhyay P, Roché HH. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010;122:409-18.
-
(2010)
Breast Cancer Res Treat
, vol.122
, pp. 409-418
-
-
Hortobagyi, G.N.1
Gomez, H.L.2
Li, R.K.3
Chung, H.C.4
Fein, L.E.5
Chan, V.F.6
-
11
-
-
84962735244
-
Pertuzumab: A step forward in treating HER2-positive breast cancer
-
Mavroudis D. Pertuzumab: a step forward in treating HER2-positive breast cancer. Transl Cancer Res. 2012;1:117-8.
-
(2012)
Transl Cancer Res
, vol.1
, pp. 117-118
-
-
Mavroudis, D.1
-
12
-
-
84866867372
-
The evolution of the role of surgery in the management of breast cancer lung metastasis
-
22934145
-
Rashid OM, Takabe K. The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis. 2012;4:420-4.
-
(2012)
J Thorac Dis
, vol.4
, pp. 420-424
-
-
Rashid, O.M.1
Takabe, K.2
-
13
-
-
84873697995
-
Breast cancer manifested by hematologic disorders
-
23205295
-
Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, et al. Breast cancer manifested by hematologic disorders. J Thorac Dis. 2012;4:650-4.
-
(2012)
J Thorac Dis
, vol.4
, pp. 650-654
-
-
Ishikawa, T.1
Shimizu, D.2
Kito, A.3
Ota, I.4
Sasaki, T.5
Tanabe, M.6
-
14
-
-
34548071359
-
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network
-
17699871 10.1158/1078-0432.CCR-07-0701 1:CAS:528:DC%2BD2sXptVGmtLg%3D
-
Ritter CA, Perez-Torres M, Rinehart C, Guix M, Dugger T, Engelman JA, et al. Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network. Clin Cancer Res. 2007;13:4909-19.
-
(2007)
Clin Cancer Res
, vol.13
, pp. 4909-4919
-
-
Ritter, C.A.1
Perez-Torres, M.2
Rinehart, C.3
Guix, M.4
Dugger, T.5
Engelman, J.A.6
-
15
-
-
33847369020
-
Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor i signaling
-
17308062 10.1158/1535-7163.MCT-06-0423 1:CAS:528:DC%2BD2sXhvVWrsbc%3D
-
Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther. 2007;6:667-74.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 667-674
-
-
Nahta, R.1
Yuan, L.X.2
Du, Y.3
Esteva, F.J.4
-
16
-
-
84876907916
-
Optimal management of brain metastases from breast cancer: Issues and considerations
-
23239265 10.1007/s40263-012-0024-z
-
Bartsch R, Berghoff AS, Preusser M. Optimal management of brain metastases from breast cancer: issues and considerations. CNS Drugs. 2013;27:121-34.
-
(2013)
CNS Drugs
, vol.27
, pp. 121-134
-
-
Bartsch, R.1
Berghoff, A.S.2
Preusser, M.3
-
17
-
-
84860003304
-
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer
-
22011930 10.1007/s11095-011-0601-8 1:CAS:528:DC%2BC3MXhtleqsLbN
-
Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29:770-81.
-
(2012)
Pharm Res
, vol.29
, pp. 770-781
-
-
Taskar, K.S.1
Rudraraju, V.2
Mittapalli, R.K.3
Samala, R.4
Thorsheim, H.R.5
Lockman, J.6
|